Personalised medicine

Personalised medicine is a high-value field, expected to expand significantly over the coming years. Strong IP strategy is key to successfully protecting emerging innovations that hold the potential to transform lives.  

The number of drug approvals in precision medicine is growing rapidly, yet this progress comes with significant legal and technical challenges. From navigating patent eligibility exclusions, to dealing with issues of ownership of data or divided infringement, while ensuring protection covers the constant evolution of assay platforms, good guidance is vital to success. 

Working with leading universities, research charities and pioneering SMEs, HGF’s large personalised medicine team delivers patent drafting and prosecution, due diligence and freedom to operate programmes, along with management of transactional and contentious matters in this revolutionary field.  

Our attorneys have a deep understanding of the challenges in this area.  With extensive in-house experience, we are able to tap into genuine insights to lead our clients’ IP strategies and advise across multiple jurisdictions. HGF’s perspective as European attorneys can help to identify global opportunities for clients from across the globe.

Latest updates

Agritech Thymes: The EPO Looks at the Morality and Patentability of Therapeutics Derived from Traditional Knowledge

This case (T2510/181) heard before the Technical Boards of Appeal at the EPO in May 2024 relates to the morality and novelty of substances of a natural origin. The invention …

Read article

Agritech Thymes: Exploring the Agritech IP landscape – past trends and future insights

The agrifood patent landscape analysis recently reported by WIPO provides interesting insights into key areas of innovation and the IP strategies being adopted. The agrifood industry, encompassing both agritech and …

Read article

Agritech Thymes: One of Europe’s oldest grape plant variety rights is invalidated

The Italian courts recently heard a case of infringement of a Plant Variety Right (PVR) held by Sun World International LLC protecting the Sugraone grape variety and of the corresponding …

Read article

New Blog Series - Agritech Thymes: A brief look at public prior use of plants in the US

In the US, plants can be protected by utility patents, plant patents and/or plant variety rights. Both types of patent are subject to the same novelty rules of USC §102, …

Read article

What's Next for CAR Cell Therapy?

The first generation CAR T cell was discovered in 1993 when the variable region of an antibody was fused to the constant regions of a T cell receptor.  Now, 20 …

Read article
Event - 30th January 2024

CAR-TCR Summit, Europe 2024

HGF are proud Event Partners of CAR-TCR Europe, which is due to go ahead from 27th – 29th February at ExCeL, Royal Victoria Dock in London. This is the European hub …

Event details

First CRISPR therapy approved for use in the UK

In an unprecedented move, the MHRA has approved a CRISPR gene editing therapy ‘Casgevy’  for the treatment of sickle cell disease and beta-thalassaemia in patients with recurrent vaso-occlusive crises. The Casgevy …

Read article
Event - 23rd - 24th April 2024

Microbiome & Probiotic R&D & Business Collaboration Forum: Europe

The 12th Microbiome & Probiotics R&D and Business Forum will take place from the 23rd-24th April at the Postillion Convention Centre in the Hague, Netherlands. This world-renowned event will see …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our personalised medicine specialists.